Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Privi Speciality Chemicals Earnings Call: Key Takeaways

Privi delivered strong FY26 performance with 22% revenue growth and 25%+ margins. Management is pivoting from a '5k revenue' goal to a more aggressive long-term trajectory via high-value specialty molecules and backward integration.

Why this was an Alfa AlertNot a filter event; results are strong but largely in line with long-term management commentary.
Highlights
Revenue growthFY26 revenue grew 22% YoY; Q4 revenue grew 15%.
MarginsEBITDA margins maintained above 25%; targeting 20%+ sustainably.
Demand visibilityStrong traction in fragrance and flavor ingredients globally.
Management confidenceHighly optimistic, emphasizing 'beyond 5k' long-term revenue vision.

Growth

FY26 revenue rose 21.7% to ₹2,583cr, while PAT surged 75% due to improved product mix and operating leverage.

Outlook

Targeting ₹5,000cr revenue and ₹1,000cr+ EBITDA within 3-4 years; Phase 1 capex completes June 2026.

Risks

Raw material volatility (pine-based) and global logistics delays remain key external sensitivities.

Source

Earnings Call filed with NSE, NSE: PRIVISCL. Summary written with AI assistance from the document.

Read the document ↗

Privi Speciality Chemicals Ltd: key numbers

Share price
₹3,594.10
Market cap
₹14,040 Cr
Revenue (annual)
₹2,564 Cr
Net profit (annual)
₹327.5 Cr
P/E (TTM)
40.1×Sector 37.5×
Promoter holding
60.60%+0.00% QoQ
FII holding
1.94%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Privi Speciality Chemicals Ltd

All →
17:49 IST BSE
Capital Structure Change

Privi Speciality Chemicals Capital Structure Change

SBI Mutual Fund sold 18,400 shares of Privi Speciality Chemicals Ltd via open market, reducing its stake from 7.3905% to 7.3434%.

18:51 IST BSE
Acquisition

Privi Speciality Chemicals Acquisition

Privi Speciality Chemicals announced an NCLT-convened meeting of equity shareholders for October 27, 2026, to consider the proposed Scheme of Amalgamation involving two transferor companies.